When researchers compared brain MRI scans of patients who had previously received gadobutrol, a common gadolinium-based contrast agent (GBCA), with patients not exposed to gadobutrol, they did not observe any visual signal intensity changes. The team noted, however, that patients who received gadobutrol had shorter T1 relaxation times of the globus pallidus.
When researchers compared brain MRI scans of patients who had previously received gadobutrol, a common gadolinium-based contrast agent (GBCA), with patients not exposed to gadobutrol, they did not observe any visual signal intensity changes. The team noted, however, that patients who received gadobutrol had shorter T1 relaxation times of the globus pallidus.